Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843373 · ClinicalTrials.gov registry record
Brain-Based Biomarkers in Response to TMS in MDD
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 54
- Enrollment target
NCT02843373: Completed study, sponsored by Stanford University.
NCT02843373 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02843373 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
The overarching goal of this research program is to elucidate causal and directional neural network- level abnormalities in depression, and how they are modulated by an individually-tailored, circuit-directed intervention. By using concurrent TMS and EEG, the investigators can overcome a major limitation of EEG - the inability to demonstrate causality. Here, we plan to recruit patients with medication-resistant depression undergoing rTMS treatment. At multiple time points, we will perform TMS-EEG to investigate the excitability and connectivity profiles of brain networks and how they are modulated during treatment. This study aims to provide objective brain network measures that can predict and track clinical response to TMS treatment. Findings from this study will be utilized to develop a novel, personalized treatment protocol based on individual brain networks.
Interventions
- DEVICE TMS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02843373
The ClinicalTrials.gov registry entry for NCT02843373 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TMS is the first listed.
NCT02843373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02843373 about?
NCT02843373 is a clinical study titled "Brain-Based Biomarkers in Response to TMS in MDD". The overarching goal of this research program is to elucidate causal and directional neural network- level abnormalities in depression, and how they are modulated by an individually-tailored, circuit-directed intervention. By using concurrent TMS and EEG, the investigators can overcome a major limit...
What is the current status of trial NCT02843373?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2016-03. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02843373?
The interventions under investigation include: TMS (DEVICE).
Who is sponsoring clinical trial NCT02843373?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.